Q-omics provides the consensus-scored FRYL profile across patient tissues and cancer cell-line models. FRYL expression is associated with patient survival in 29 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, FRYL is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, FRYL protein abundance shows 26,209 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, HNSC, and LSCC as cancer lineages where FRYL shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FRYL — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FRYL survival associations across molecular data types. FRYL RNA expression shows survival associations in the most cancer types (29), followed by mutation status (5) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FRYL RNA expression–survival associations across cancer types. High FRYL expression shows unfavorable associations in LGG and CESC, but favorable associations in KIRC, BRCA, READ and HNSC. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for FRYL RNA expression.
This table summarizes FRYL tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 11. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FRYL. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FRYL shows lower tumor expression in COAD, THCA and LUSC and higher tumor expression in HNSC, KIRC and LIHC. The HNSC box plot shows higher FRYL RNA expression in tumor versus normal tissue (log2 FC = +0.863, t-test p < 0.001).
This table shows molecular features associated with FRYL in patient tissues and cancer cell lines. In patient samples, FRYL shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, FRYL RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
